Angiogenesis, the formation of new blood vessels, is a complex and dynamic process
regulated by various pro-and anti-angiogenic molecules, which plays a crucial role in tumor …

Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring
epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer …

Simple Summary Accumulation of excess fluid in the abdomen typically indicates abnormal
function or disease, such as cancer, in the underlying tissues. This accumulation of fluid, or …

The use of nanomedicine for antitumor therapy has been extensively investigated for a long
time. Enhanced permeability and retention (EPR) effect-mediated drug delivery is currently …

The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth
factor receptor (EGFR) have expanded the range of treatment options for metastatic …

It is clear that tumor cells do not act alone but in close interaction with the extracellular matrix
and with stromal cells in the tumor microenvironment (TME). As our understanding of tumor …

Multiple cellular pathways influence the growth and metastatic potential of tumors. This
creates heterogeneity, redundancy, and the potential for tumors to bypass signaling pathway …

Angiogenesis is known as one of the hallmarks of cancer. Multiple lines evidence indicated
that vascular endothelium growth factor (VEGF) is a key player in the progression of …

Purpose Mutations affecting the KRAS gene are established predictive markers of outcome
with anti–epithelial growth factor receptor (EGFR) antibodies in advanced colorectal cancer …

The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been …